Skip to main content

Espen A. Haavardsholm

Professor |
Center manager REMEDY https://orcid.org/0000-0002-1427-4745

See Google Scholar profile

See publications in PubMed

Education

Doctor at the University of Oslo (professional study in medicine)
Doctoral degree at the Department of Clinical Medicine, University of Oslo

Score

Head of Centre, Research Center for Treatment in Rheumatology and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital
Head of department for research and innovation, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital
Professor II, Department of Clinical Medicine, University of Oslo

Field of interest

Rheumatology
Musculoskeletal diseases
Osteoarthritis
Randomized clinical trials
Register studies
Image diagnostics
Translational research

Other

President, Scandinavian Society of Rheumatology
Chairman, Stiftelsen Scandinavian Rheumatology Association
Board member, Norwegian Rheumatology Association

Email

This email address is protected from programs that collect email addresses. You need JavaScript enabled to view it.

Telephone

visiting address

Diakonhjemmet hospital
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postal address

Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP1 - Optimized medical interventions

ARCTIC FORWARD

10-year follow-up of patients with rheumatoid arthritis who received structured treatment-to-target therapy in the early disease phase.

Project Manager:

Siri Lillegraven

WP1 - Optimized medical interventions

ARCTIC REWIND

10-year follow-up of patients with rheumatoid arthritis who received structured treatment-to-target therapy in the early disease phase.

Project Manager:

Espen A. Haavardsholm

WP2 - PPhenotyping for personalized medicine

BIKE

Biopsies of synovitis in the knee joint from patients with RA and OA

Project Manager:

Hilde Berner Hammer

WP1 - Optimized medical interventions

MERINO

Methotrexate in the treatment of erosive hand osteoarthritis

Project Manager:

Ida Bos-Haugen

WP1 - Optimized medical interventions

MethMax

Maximization of treatment effect

Project Manager:

Siri Lillegraven

WP1 - Optimized medical interventions

MinJIA

Strategies for personalized treatment of juvenile idiopathic arthritis (JIA)

Project Manager:

Berit Flatø

WP1 - Optimized medical interventions

NORWAY CACTUS

Comparison of treatment strategies in carpal tunnel syndrome

Project Manager:

Hilde Berner Hammer

WP6 - Dechiphering long-term outcomes

NOR-DMARD

The Norwegian register for antirheumatic drugs

Project Manager:

Tore K. Kvien

WP2 - PPhenotyping for personalized medicine

NOR DRUM

The Norwegian study for therapeutic drug monitoring

Project Manager:

Espen A. Haavardsholm

WP5 - Innovative approaches to remote care

NOR Flare

Distance follow-up of patients with rheumatoid arthritis

Project Manager:

Anne Therese Tveter

WP6 - Dechiphering long-term outcomes

NOR Gout

Gout in Norway

Project Manager:

Till Uhlig

WP1 - Optimized medical interventions

NOR Sprint

Follow-up of newly diagnosed patients with psoriatic arthritis with and without imaging

Project Manager:

Siri Lillegraven

WP2 - PPhenotyping for personalized medicine

Nor-vaC

Immunological response to COVID-19 vaccine in patients on immunosuppressive treatment

Project Manager:

Guro Løvik Goll

WP1 - Optimized medical interventions

NORTH STAR

The Nordic study of strategy tests and registries for rheumatic diseases

Project Manager:

Espen A. Haavardsholm

WP1 - Optimized medical interventions

PICASSO

Treatment of painful inflammatory carpometacarpal-1 osteoarthritis with intra-articular steroids, saline or occupational therapy

Project Manager:

Ida K. Bos-Haugen

WP1 - Optimized medical interventions

RA DRUM

Therapeutic drug monitoring in patients with rheumatoid arthritis (RA-DRUM)

Project Manager:

Silje Watterdal Syversen

WP5 - Innovative approaches to remote care

ReMonit

Digital home follow-up of patients with spondyloarthritis

Project Manager:

Nina Østerås

WP2 - PPhenotyping for personalized medicine

RIMRA

Rheumatic immune-related side effects in patients treated with immunotherapy

Project Manager:

Marte Schrumpf Heiberg

WP1 - Optimized medical interventions

SQUEEZE

Maximizing the effect of prescription drugs in rheumatoid arthritis

Project Manager:

Espen A. Haavardsholm

WP2 - PPhenotyping for personalized medicine

START

Stratification of acute inflammatory arthritis

Project Manager:

Silje Watterdal Syversen

Publications

Publications taken from the National Science Archive (NVA):

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomized controlled, non-inferiority trial

Kaja Eriksrud Kjørholt, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad

The Lancet Rheumatology

2024

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyzes of the randomised, controlled NOR-DRUM trials

Marthe Kirkesæther Brun, Johanna Gehin, Kristin Reine Hammersbøen, David Warren, Rolf Klaasen, Joseph Sexton

The Lancet Rheumatology

2024

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

Hassen Kared, Ingrid Jyssum, Amin Alirezaylavasani, Ingrid Marie Egner, Trung The Tran, Lisa Tietze

Frontiers in Immunology

2024

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

Karen Holten, Nina Paulshus Sundlisæter, Joseph Sexton, Lena Bugge Nordberg, Till Uhlig, Tore Kristian Aaserud Kvien

RMD Open

2024

Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study

Violetta Dubovyk, Georgios K. Vasileiadis, Tahzeeb Fatima, Yuan Zhang, Meliha Crnkic Kapetanovic, Alf Kastbom

RMD Open

2024

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

Hilde Sofie Sager Ørbo, Kristin Reine Hammersbøen, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen

RMD Open

2024

Glossary of national professional guidelines from the Norwegian Directorate of Health

Lise Mørkved Helsingen, Eline Aurvoll Langeland, Synne Eline Rotihaug Pisani, Per Olav Vandvik, Espen A. Haavardsholm, Ulrik Fredrik Malt

Journal of the Norwegian Medical Association

2024

Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial

Kristina Lend, Frieda A. Koopman, Jon Lampa, Gerrit Jansen, Merete L. Hetland, Till Uhlig

Arthritis & Rheumatology

2023

Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial

Inger Jorid Berg, Anne Therese Tveter, Gunnstein Bakland, Sarah Hakim, Eirik Kristianslund, Siri Lillegraven

JMIR Research Protocols

2023

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study

Till Uhlig, Lars Fridtjof Karoliussen, Joseph Sexton, Tore Kristian Aaserud Kvien, Espen A. Haavardsholm, Hilde Berner Hammer

RMD Open

2023

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

Ingrid Jyssum, Johanna Gehin, Joseph Sexton, Eirik Kristianslund, Yi Hu, David Warren

Rheumatology

2023

Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study

Till Uhlig, Lars Fridtjof Karoliussen, Joseph Sexton, Sella Aarrestad Provan, Tore Kristian Aaserud Kvien, Espen A. Haavardsholm

Rheumatology

2023

Effect of tapered versus stable treatment with tumor necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Åse Lexberg

Annals of the Rheumatic Diseases

2023

Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019)

Alen Brkic, Andreas P Diamantopoulos, Mari Hoff, Espen A. Haavardsholm, Bjørg Tilde Svanes Fevang, Lene Kristin Brekke

BMC Health Services Research

2023

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomized controlled NORD-STAR trial

Mikkel Østergaard, Ronald F Van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf, Dan C Nordström

Annals of the Rheumatic Diseases

2023

Calprotectin, a sensitive marker of inflammation, is robustly assessed in plasma from patients with early or established rheumatoid arthritis by use of different laboratory methods

Hilde Berner Hammer, Sigve Lars Pedersen, Maria Karolina Jonsson, Linda Mathsson-Alm, Isabel Gehring, Joseph Sexton

Scandinavian Journal of Clinical and Laboratory Investigation

2023

Beliefs about medicines in gout patients: results from the NOR-Gout 2-year study

Till Uhlig, Lars Fridtjof Karoliussen, Joseph Sexton, Tore Kristian Aaserud Kvien, Espen A. Haavardsholm, WJ Taylor

Scandinavian Journal of Rheumatology

2023

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and Excellent Disease Control

Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Daniel H. Solomon, Désirée Van Der Heijde

Journal of the American Medical Association (JAMA)

2023

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases

Marthe Kirkesæther Brun, Kristin Reine Hammersbøen, Marte Kathrine Viken, Grethe-Elisabeth Stenvik, Rolf Klaasen, Johanna Gehin

Journal of Internal Medicine

2023

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

Kristin H. Bjørlykke, Hilde Sofie Sager Ørbo, Anne Therese Tveter, Ingrid Jyssum, Joseph Sexton, Trung Tran

The Lancet Rheumatology

2022

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert BM Landewé, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha

Annals of the Rheumatic Diseases

2022

All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study

Anne Mirjam Kerola, Amirhossein Kazemi, Silvia Christin Hellerud Rollefstad, Siri Lillegraven, Joseph Sexton, Grunde Wibetoe

Rheumatology

2022

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Ingrid Egeland Christensen, Trung Tran

RMD Open

2022

Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study

Till Uhlig, Lars Fridtjof Karoliussen, Joseph Sexton, Tore Kristian Kvien, Espen A. Haavardsholm, F. Perez-Ruiz

Clinical Rheumatology

2022

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Ingrid Egeland Christensen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Trung Tran, Siri Mjaaland

BMC Medicine

2022

The MCP2 and the wrist plus two extensor compartments are the most affected and responsive joints/tendons out of the US7 score in patients with rheumatoid arthritis-an observational study

AF Podewski, AM Glimm, I. Fischer, GAW Bruyn, P. Hanova, Hilde Berner Hammer

Arthritis Research & Therapy

2022

Risk factors for anti-drug antibody formation to infliximab: Secondary analyzes of a randomized controlled trial

Marthe Kirkesæther Brun, Guro Løvik Goll, Kristin Kaasen Jørgensen, Joseph Sexton, Johanna Elin Gehin, Øystein Sandanger

Journal of Internal Medicine

2022

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Trung Tran, Joseph Sexton, Sella Aarrestad Provan

Arthritis & Rheumatology

2022

Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomized controlled trial

Kristina Lend, Ronald F van Vollenhoven, Jon Lampa, Merete Lund Hetland, Espen A. Haavardsholm, Dan Nordström

The Lancet Rheumatology

2022

Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data

Vibeke Norvang, Espen A. Haavardsholm, Sara K. Tedeschi, Houchen Lyu, Joseph Sexton, Maria Dahl Mjaavatten

BMC Medical Research Methodology

2022

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study

Hilde Berner Hammer, Silvia Christin Hellerud Rollefstad, Anne Grete Semb, Gro Elisabeth Jensen, Lars Fridtjof Karoliussen, L Terslev

RMD Open

2022

Impact of delayed type hypersensitivity arthritis on development of heart failure by aortic constriction in mice

Theis Christian Tønnessen, Arne Olav Melleby, Ida Marie Hauge-Iversen, Emil Knut Stenersen Espe, Muhammad Shakil Ahmed, Thor Ueland

PLOS ONE

2022

Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents

AM Kerola, Silvia Christin Hellerud Rollefstad, Amirhossein Kazemi, Grunde Wibetoe, Joseph Sexton, N. Mars

Scandinavian Journal of Rheumatology

2022

One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study

Till Uhlig, Lars Fridtjof Karoliussen, Joseph Sexton, Tore Kristian Kvien, Espen A. Haavardsholm, Fernando Perez-Ruiz

Arthritis Research & Therapy

2022

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study

Nina Beate Paulshus Sundlisæter, Ulf Gunnar Sundin, Anna-Birgitte Aga, Joseph Sexton, Hilde Berner Hammer, Till Uhlig

RMD Open

2022

Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs

Alen Brkic, Andreas P Diamantopoulos, Espen A. Haavardsholm, Bjørg Tilde Svanes Fevang, Lene Kristin Brekke, Liz Paucar Loli

BMC Health Services Research

2022

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Ingrid Jyssum, Hassen Kared, Trung Tran, Anne Therese Tveter, Sella Aarrestad Provan, Joseph Sexton

The Lancet Rheumatology

2021

Two-year reduction of dual-energy CT urate deposits during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.

Till Uhlig, Tron Hovind Eskild, Lars Fridtjof Karoliussen, Joseph Sexton, Tore Kristian Kvien, Espen A. Haavardsholm

Rheumatology

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, Marthe Kirkesæther Brun, Øystein Sandanger, Kristin Reine Hammersbøen

Journal of the American Medical Association (JAMA)

2021

Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis

Jonathan Aldridge, Anna-Carin Lundell, Kerstin Andersson, Linda Mark, Merete Lund Hetland, Mikkel Østergaard

Clinical and Experimental Rheumatology

2021

Incidence, sociodemographic factors and treatment penetration of rheumatoid arthritis and psoriatic arthritis in Norway.

Anne Mirjam Kerola, Joseph Sexton, Grunde Wibetoe, Silvia Christin Hellerud Rollefstad, Cynthia Sue Crowson, Nina Mars

Seminars in Arthritis & Rheumatism

2021

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.

Marit Stockfelt, Anna-Carin Lundell, Merete Lund Hetland, Mikkel Østergaard, Till Uhlig, Marte Schrumpf

Arthritis Research & Therapy

2021

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

Karen Holten, Nina Beate Paulshus Sundlisæter, Siri Lillegraven, Joseph Sexton, Lena Kristine Bugge Nordberg, Ellen Moholt

Annals of the Rheumatic Diseases

2021

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: Achievements of the urate target levels and predictors of obtaining this target

Till Uhlig, Lars Fridtjof Karoliussen, Joseph Sexton, Tove Borgen, Espen A. Haavardsholm, Tore Kristian Kvien

RMD Open

2021

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial

Siri Lillegraven, Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad

Journal of the American Medical Association (JAMA)

2021

MicroRNA Expression Differences in Blood-Derived CD19+ B Cells of Methotrexate Treated Rheumatoid Arthritis Patients

Fatima Heinicke, Xiangfu Zhong, Siri Tennebø Flåm, Johannes Breidenbach, Magnus Leithaug, Marthe Thoresen Mæhlen

Frontiers in Immunology

2021

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy

Ulf Gunnar Sundin, Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Lena Kristine Bugge Nordberg, Hilde Berner Hammer

RMD Open

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Øystein Sandanger, Joseph Sexton, Inge Christoffer Olsen

Journal of the American Medical Association (JAMA)

2021

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)

Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Øystein Sandanger, Johanna Elin Gehin

Trials

2020

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial

Merete Lund Hetland, Espen A. Haavardsholm, Anna Rudin, Dan C. Nordström, Michael Nurmohamed, Bjorn Gudbjornsson

The BMJ

2020

Conventional versus ultrasound treat to target: No difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis

Ulf Gunnar Sundin, Anna-Birgitte Aga, Øivind Skare, Lena Kristine Bugge Nordberg, Till Uhlig, Hilde Berner Hammer

Rheumatology

2020

Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study

Hilde Berner Hammer, Lars Fridtjof Karoliussen, Lene Terslev, Espen A Haavardsholm, Tore Kristian Kvien, Till Uhlig

Annals of the Rheumatic Diseases

2020

The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial

Elisabeth Gjefsen, Lars Christian Haugli Bråten, Guro Løvik Goll, Monica Wigemyr, Nils Bolstad, Morten Valberg

BMC Musculoskeletal Disorders

2020

Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: Exploratory analyzes from the NOR-SWITCH main and extension trials

Kristin Kaasen Jørgensen, Guro Løvik Goll, Joseph Sexton, Nils Bolstad, Inge Christoffer Olsen, Øivind Wessel Asak

BioDrugs

2020

Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-to-Target Strategies

Vibeke Norvang, Gina Charlotte Hetland Brinkmann, Kazuki Yoshida, Siri Lillegraven, Anna-Birgitte Aga, Joseph Andrew Sexton

Arthritis & Rheumatology

2020

Rheumatoid Arthritis Patients, Both Newly Diagnosed and Methotrexate Treated, Show More DNA Methylation Differences in CD4+ Memory Than in CD4+ Naïve T Cells

Kari Guderud, Line Hagen Sunde, Siri Tennebø Flåm, Marthe Thoresen Mæhlen, Maria Dahl Mjaavatten, Siri Lillegraven

Frontiers in Immunology

2020

Trends in All-Cause and Cardiovascular Mortality in Patients With Incident Rheumatoid Arthritis: A 20-year Follow-Up Matched Case-Cohort Study

Sella Aarrestad Provan, Siri Lillegraven, Joseph Sexton, Kristin Angel, Cathrine Austad, Espen A. Haavardsholm

Rheumatology

2019

Validity and responsiveness of combined inflammation and combined joint damage scores based on the OMERACT rheumatoid arthritis MRI scoring system (RAMRIS)

Ulf Gunnar Sundin, Mikkel Østergaard, Daniel Glinatsi, Anna-Birgitte Aga, Kim Hørslev-Petersen, Merete L. Hetland

Journal of Rheumatology

2019

Peptidylarginine deiminase 4 (PAD4) activity in early rheumatoid arthritis

Maria Karolina Jonsson, Tomasz Tadeusz Kantyka, Katherine Falkowski, Ardita Aliko, Anna-Birgitte Aga, Siri Lillegraven

Scandinavian Journal of Rheumatology

2019

Subclinical treatment targets in rheumatology: Lessons from randomized clinical trials in rheumatoid arthritis

Siri Lillegraven, Espen A. Haavardsholm

Rheumatic Disease Clinics of North America

2019

Assessing synovitis in the hands in patients with rheumatoid arthritis by ultrasound: an agreement study exploring the most inflammatory active side from two Norwegian trials

Lene Terslev, Robin Christensen, Anna-Birgitte Aga, Joseph Sexton, Espen A. Haavardsholm, Hilde Berner Hammer

Arthritis Research & Therapy

2019

Swollen, but not tender joints, are independently associated with ultrasound synovitis: Results from a longitudinal observational study of patients with established rheumatoid arthritis

Hilde Berner Hammer, Brigitte Michelsen, Joseph Sexton, Ida Kristin Haugen, Sella Aarrestad Provan, Espen A. Haavardsholm

Annals of the Rheumatic Diseases

2019

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial

Guro Løvik Goll, Kristin Kaasen Jørgensen, Joseph Sexton, Inge Christoffer Olsen, Nils Bolstad, Espen A. Haavardsholm

Journal of Internal Medicine

2019

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial

Lena Kristine Bugge Nordberg, Siri Lillegraven, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Elisabeth Lie

RMD Open

2018

Comparative analyzes of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyzes from the ARCTICstudy

Karen Holten, Joseph Sexton, Tore Kristian Kvien, Anna-Birgitte Aga, Espen A. Haavardsholm

RMD Open

2018

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study

Vibeke Norvang, Joseph Sexton, Eirik Kristianslund, Inge Christoffer Olsen, Till Uhlig, Gunnstein Bakland

RMD Open

2018

Confiance des rhumatologues quant au passage a un biosimilaire

Guro Løvik Goll, Espen A. Haavardsholm, Tore Kristian Kvien

Revue du Rhumatisme (Edition Francaise)

2018

Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol

Nina Beate Paulshus Sundlisæter, Inge Christoffer Olsen, Anna-Birgitte Aga, Hilde Berner Hammer, Till Uhlig, Desirée van der Heijde

Rheumatology

2018

The impact of ultrasound on the use and efficacy of intraarticular glucocorticoid injections in early rheumatoid arthritis: Secondary analyzes from a randomized trial examining the benefit of ultrasound in a clinical tight control regimen

Lena Kristine Bugge Nordberg, Siri Lillegraven, Anna-Birgitte Aga, Joseph Sexton, Elisabeth Lie, Hilde Berner Hammer

Arthritis & Rheumatology

2018

The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy

Maria Karolina Jonsson, Aase Haj Hensvold, Monika Hansson, Anna-Birgitte Aga, Joseph Sexton, Linda Mathsson-Alm

Arthritis Research & Therapy

2018

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes

Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Inge Christoffer Olsen, Hilde Berner Hammer, Till Uhlig, Desirée van der Heijde

Annals of the Rheumatic Diseases

2018

Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: Study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study

Daniel Glinatsi, Marte Schrumpf, Anna Rudin, Dan C. Nordström, Espen A. Haavardsholm, Björn Gudbjörnsson

Trials

2017

The OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging (MRI) Scoring System: Updated Recommendations by the OMERACT MRI in Arthritis Working Group

Mikkel Østergaard, Charles G. Peterfy, Paul Bird, Frédérique Gandjbakhch, Daniel Glinatsi, Iris Eshed

Journal of Rheumatology

2017

Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise

Daniel Glinatsi, Paul Bird, Frédérique Gandjbakhch, Espen A. Haavardsholm, Charles G. Peterfy, Edwar M. Vital

Journal of Rheumatology

2017

Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis

Maria Karolina Jonsson, Nina Beate Paulshus Sundlisæter, Hilde Haugedal Nordal, Hilde Berner Hammer, Anna-Birgitte Aga, Inge Christoffer Olsen

Annals of the Rheumatic Diseases

2017

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll, Merete Lorentzen, Nils Bolstad, Espen A. Haavardsholm

The Lancet

2017

Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria

Lena Kristine Bugge Nordberg, Siri Lillegraven, Elisabeth Lie, Anna-Birgitte Aga, Inge Christoffer Olsen, Hilde Berner Hammer

Annals of the Rheumatic Diseases

2017

Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology

Christian Beyer, Sofia Ramiro, Francisca Sivera, Peter Mandl, Pedro M. Machado, Caroline Ospelt

RMD Open

2016

Ultrasound in the management of rheumatoid arthritis: ARCTIC randomized controlled strategy trial

Espen A. Haavardsholm, Anna-Birgitte Aga, Inge Christoffer Olsen, Siri Lillegraven, Hilde Berner Hammer, Till Uhlig

The BMJ

2016

Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach

Anna-Birgitte Aga, Hilde Berner Hammer, Inge Christoffer Olsen, Till Uhlig, Tore Kristian Kvien, Desirée van der Heijde

RMD Open

2016

Diagnosis and management of rheumatoid arthritis; What is the current role of established and new imaging techniques in clinical practice?

Maria Antonietta D'Agostino, Espen A. Haavardsholm, Conny J. van der Laken

Baillière's Best Practice & Research : Clinical Rheumatology

2016